Literature DB >> 19925901

Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses.

Peter D Hedlin1, Neil R Cashman, Li Li, Jyotsana Gupta, Lorne A Babiuk, Andrew A Potter, Philip Griebel, Scott Napper.   

Abstract

Transmissible spongiform encephalopathies (TSEs) depend on misfolding of a normal cellular protein (PrP(C)) to an infectious conformation (PrP(Sc)). Targeting PrP(Sc) may represent an effective strategy for immunotherapy while avoiding consequences associated with immune responses to self-proteins. A weakly immunogenic epitope of PrP(C) (YYR), which induces PrP(Sc)-specific antibodies, is used as a starting point for vaccine development. Through optimization of epitope, as well as formulation/delivery, we enhance immunogenicity while retaining PrP(Sc) specificity. In particular, QVYYRPVDQYSNQN, presented by a leukotoxin carrier protein, emerges as a strong vaccine candidate. A vaccine representing this construct induces consistent and sustained serum PrP(Sc)-specific IgG antibody responses following two vaccinations. Antigen specific antibodies are also present within cerebral spinal fluid and mucosal secretions. These characteristics provide a foundation for development of a TSE vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925901     DOI: 10.1016/j.vaccine.2009.10.134

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  In vitro neutralization of prions with PrP(Sc)-specific antibodies.

Authors:  Ryan Taschuk; Jacques Van der Merwe; Kristen Marciniuk; Andrew Potter; Neil Cashman; Philip Griebel; Scott Napper
Journal:  Prion       Date:  2015       Impact factor: 3.931

2.  Binding of bovine T194A PrP(C) by PrP(Sc)-specific antibodies: potential implications for immunotherapy of familial prion diseases.

Authors:  Claudia A Madampage; Pekka Määttänen; Kristen Marciniuk; Robert Brownlie; Olga Andrievskaia; Andrew Potter; Neil R Cashman; Jeremy S Lee; Scott Napper
Journal:  Prion       Date:  2013-05-31       Impact factor: 3.931

3.  PrP(Sc)-specific antibodies do not induce prion disease or misfolding of PrP(C) in highly susceptible Tga20 mice.

Authors:  Pekka Määttänen; Ryan Taschuk; Li Ross; Kristen Marciniuk; Lisa Bertram; Andrew Potter; Neil R Cashman; Scott Napper
Journal:  Prion       Date:  2013-10-08       Impact factor: 3.931

4.  Nanopore analysis reveals differences in structural stability of ovine PrP(C) proteins corresponding to scrapie susceptible (VRQ) and resistance (ARR) genotypes.

Authors:  Claudia Avis Madampage; Kristen Marciniuk; Pekka Määttänen; Neil R Cashman; Andrew Potter; Jeremy S Lee; Scott Napper
Journal:  Prion       Date:  2014-01-08       Impact factor: 3.931

5.  EpIC: a rational pipeline for epitope immunogenicity characterization.

Authors:  Kristen Marciniuk; Brett Trost; Scott Napper
Journal:  Bioinformatics       Date:  2015-03-06       Impact factor: 6.937

6.  Prion Diseases in Animals: Poster Abstracts.

Authors: 
Journal:  Prion       Date:  2013 Apr/May       Impact factor: 3.931

7.  Could immunomodulation be used to prevent prion diseases?

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

Review 8.  The role of genetics in chronic wasting disease of North American cervids.

Authors:  Stacie J Robinson; Michael D Samuel; Katherine I O'Rourke; Chad J Johnson
Journal:  Prion       Date:  2012-04-01       Impact factor: 3.931

Review 9.  Immunomodulation for prion and prion-related diseases.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

Review 10.  The role of prion strain diversity in the development of successful therapeutic treatments.

Authors:  Sara A M Holec; Alyssa J Block; Jason C Bartz
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-28       Impact factor: 3.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.